Brazil · Delayed Price · Currency is BRL Revance Therapeutics Statistics
Total Valuation
Dexco has a market cap or net worth of BRL 4.68 billion. The enterprise value is 11.06 billion.
| Market Cap | 4.68B |
| Enterprise Value | 11.06B |
Important Dates
The last earnings date was Wednesday, August 6, 2025.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | Mar 18, 2025 |
Share Statistics
Dexco has 808.37 million shares outstanding. The number of shares has increased by 0.21% in one year.
| Current Share Class | 808.37M |
| Shares Outstanding | 808.37M |
| Shares Change (YoY) | +0.21% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 12.89% |
| Owned by Institutions (%) | 28.63% |
| Float | 395.06M |
Valuation Ratios
The trailing PE ratio is 18.22 and the forward PE ratio is 14.18. Dexco's PEG ratio is 0.51.
| PE Ratio | 18.22 |
| Forward PE | 14.18 |
| PS Ratio | 0.57 |
| PB Ratio | 0.66 |
| P/TBV Ratio | 0.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 3.77 |
| PEG Ratio | 0.51 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.71, with an EV/FCF ratio of -11,766.20.
| EV / Earnings | 42.90 |
| EV / Sales | 1.35 |
| EV / EBITDA | 6.71 |
| EV / EBIT | 24.67 |
| EV / FCF | -11,766.20 |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of 1.10.
| Current Ratio | 1.37 |
| Quick Ratio | 0.88 |
| Debt / Equity | 1.10 |
| Debt / EBITDA | 4.98 |
| Debt / FCF | -8,295.05 |
| Interest Coverage | 0.47 |
Financial Efficiency
Return on equity (ROE) is 3.94% and return on invested capital (ROIC) is 1.53%.
| Return on Equity (ROE) | 3.94% |
| Return on Assets (ROA) | 1.26% |
| Return on Invested Capital (ROIC) | 1.53% |
| Return on Capital Employed (ROCE) | 2.52% |
| Revenue Per Employee | 576,413 |
| Profits Per Employee | 18,121 |
| Employee Count | 14,228 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 3.94 |
Taxes
In the past 12 months, Dexco has paid 89.17 million in taxes.
| Income Tax | 89.17M |
| Effective Tax Rate | 24.96% |
Stock Price Statistics
The stock price has decreased by -16.95% in the last 52 weeks. The beta is 0.34, so Dexco's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | -16.95% |
| 50-Day Moving Average | 5.58 |
| 200-Day Moving Average | 6.08 |
| Relative Strength Index (RSI) | 60.17 |
| Average Volume (20 Days) | 3,509,040 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Dexco had revenue of BRL 8.20 billion and earned 257.83 million in profits. Earnings per share was 0.32.
| Revenue | 8.20B |
| Gross Profit | 1.94B |
| Operating Income | 365.02M |
| Pretax Income | 357.26M |
| Net Income | 257.83M |
| EBITDA | 1.52B |
| EBIT | 365.02M |
| Earnings Per Share (EPS) | 0.32 |
Balance Sheet
The company has 1.49 billion in cash and 7.80 billion in debt, giving a net cash position of -6.15 billion or -7.60 per share.
| Cash & Cash Equivalents | 1.49B |
| Total Debt | 7.80B |
| Net Cash | -6.15B |
| Net Cash Per Share | -7.60 |
| Equity (Book Value) | 7.11B |
| Book Value Per Share | 8.50 |
| Working Capital | 1.31B |
Cash Flow
In the last 12 months, operating cash flow was 1.24 billion and capital expenditures -1.24 billion, giving a free cash flow of -940,000.
| Operating Cash Flow | 1.24B |
| Capital Expenditures | -1.24B |
| Free Cash Flow | -940,000 |
| FCF Per Share | -0.00 |
Margins
Gross margin is 23.69%, with operating and profit margins of 4.45% and 3.14%.
| Gross Margin | 23.69% |
| Operating Margin | 4.45% |
| Pretax Margin | 4.36% |
| Profit Margin | 3.14% |
| EBITDA Margin | 18.58% |
| EBIT Margin | 4.45% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.22, which amounts to a dividend yield of 3.72%.
| Dividend Per Share | 0.22 |
| Dividend Yield | 3.72% |
| Dividend Growth (YoY) | -81.61% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 90.71% |
| Buyback Yield | -0.21% |
| Shareholder Yield | 3.48% |
| Earnings Yield | 5.51% |
| FCF Yield | -0.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 21, 2022. It was a forward split with a ratio of 1.1.
| Last Split Date | Dec 21, 2022 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
Dexco has an Altman Z-Score of 1.12 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.12 |
| Piotroski F-Score | 7 |